{"id":771,"date":"2015-11-01T12:00:00","date_gmt":"2015-11-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom"},"modified":"2015-11-01T12:00:00","modified_gmt":"2015-11-01T11:00:00","slug":"intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom","title":{"rendered":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom"},"content":{"rendered":"<p>Zusammenfassung: Die Indikation f\u00fcr den Beginn einer medikament\u00f6sen Therapie zur Androgendeprivation (AD) bei Patienten mit Prostatakarzinom h\u00e4ngt vor allem ab von der Krankheitssituation, den vorhandenen Symptomen, der Vorbehandlung und dem Risikoprofil. Sie sollte gem\u00e4\u00df den aktuellen Leitlinien zur\u00fcckhaltend gestellt werden. Au\u00dferdem m\u00fcssen die Patienten gr\u00fcndlich \u00fcber Nutzen und Risiken aufgekl\u00e4rt werden. Ergebnisse einer aktuellen Metaanalyse [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die Indikation f\u00fcr den Beginn einer medikament\u00f6sen Therapie zur Androgendeprivation (AD) bei Patienten mit Prostatakarzinom h\u00e4ngt vor allem ab von der Krankheitssituation, den vorhandenen Symptomen, der Vorbehandlung und dem Risikoprofil. Sie sollte gem\u00e4\u00df den aktuellen Leitlinien zur\u00fcckhaltend gestellt werden. Au\u00dferdem m\u00fcssen die Patienten gr\u00fcndlich \u00fcber Nutzen und Risiken aufgekl\u00e4rt werden. Ergebnisse einer aktuellen Metaanalyse [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1994,1992,1320,1319,395,1993,2001,2003,1998,1995,1997,1996,1999,2002,2000,222,500,567],"class_list":["post-771","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abirateron","tag-androgen-entzugstherapie","tag-androgene","tag-antiandrogene","tag-bicalutamid","tag-enzalutamid","tag-gnrh","tag-gnrh-agonisten","tag-gnrh-antagonisten","tag-gonadorelin","tag-gonadorelin-agonisten","tag-gonadorelin-antagonisten","tag-gonadotropin-releasing-hormon","tag-gonadotropin-releasing-hormon-agonisten","tag-gonadotropin-releasing-hormon-antagonisten","tag-karzinome","tag-prostatakarzinom","tag-testosteron"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=771"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/771\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}